Presentation is loading. Please wait.

Presentation is loading. Please wait.

Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel.

Published byDonald Rose Modified over 6 years ago

Similar presentations

Presentation on theme: "Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel."— Presentation transcript:

1 Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future  Rudolf Valenta, MD, Raffaela Campana, PhD, Margit Focke-Tejkl, PhD, Verena Niederberger, MD  Journal of Allergy and Clinical Immunology  Volume 137, Issue 2, Pages (February 2016) DOI: /j.jaci Copyright © 2015 The Authors Terms and Conditions

2 Fig 1 Requirements for improved allergy vaccines.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

3 Fig 2 Steps toward improvement of allergy vaccines.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

4 Fig 3 Schematic representation of the development of BM32, a recombinant B-cell epitope–based grass pollen allergy vaccine. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2015 The Authors Terms and Conditions

Download ppt "Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel."

Similar presentations

Faecalibacterium prausnitzii subspecies–level dysbiosis in the human gut microbiome underlying atopic dermatitis Han Song, PhD, Young Yoo, MD, PhD, Junghyun.

Faecalibacterium prausnitzii subspecies–level dysbiosis in the human gut microbiome underlying atopic dermatitis Han Song, PhD, Young Yoo, MD, PhD, Junghyun.
Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality  Allan Linneberg,

Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality  Allan Linneberg,
Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines 

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines 
Allergen immunotherapy: A practice parameter third update

Allergen immunotherapy: A practice parameter third update
Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality  Allan Linneberg,

Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality  Allan Linneberg,
Advances in food allergy in 2015

Advances in food allergy in 2015
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy  Margarete Focke-Tejkl, PhD, Milena.

Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy  Margarete Focke-Tejkl, PhD, Milena.
Major rabbit allergen Ory c 3: What could be its possible role as a sensitizing agent in real life?  Gennaro Liccardi, MD, Antonello Salzillo, MD, Maria.

Major rabbit allergen Ory c 3: What could be its possible role as a sensitizing agent in real life?  Gennaro Liccardi, MD, Antonello Salzillo, MD, Maria.
Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule  Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,

Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule  Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,
Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Practice Notes from the AAAI

Practice Notes from the AAAI
Safety of allergen immunotherapy: A 10-year prospective study

Safety of allergen immunotherapy: A 10-year prospective study
Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines 

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines 
A history of pollen mapping and surveillance: The relations between natural history and clinical allergy  Gregg Mitman, PhD  Journal of Allergy and Clinical.

A history of pollen mapping and surveillance: The relations between natural history and clinical allergy  Gregg Mitman, PhD  Journal of Allergy and Clinical.
Recombinant allergens: What does the future hold?

Recombinant allergens: What does the future hold?
Molecular determinants of allergen-induced effector cell degranulation

Molecular determinants of allergen-induced effector cell degranulation
Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Similar presentations

Ads by Google